Can’t Ignore: inContact, Inc., SunEdison (NYSE:SUNE), Nokia Corporation (NYSE:NOK), Kite Pharma (NASDAQ:KITE), Synchrony Financial (NYSE:SYF)

Posted by on Nov 04, 2015

inContact, Inc. (NASDAQ:SAAS) shares increased 2.81% in last trading session and ended the day at $9.50. SAAS Gross Margin is 49.60% and its has a return on assets of -12.10%. inContact, Inc. (NASDAQ:SAAS) quarterly performance is -1.04%.

On 29 October, inContact, Inc. (NASDAQ:SAAS) reported record financial results for the third quarter ended September 30, 2015. Software segment revenue totaled $36.7 million for the quarter ended September 30, 2015, an increase of 40% from $26.3 million in Q3 2014.

SunEdison, Inc. (NYSE:SUNE) shares increased 2.70% in last trading session and ended the day at $7.98. SUNE Gross Margin is 13.80% and its has a return on assets of -8.70%. SunEdison, Inc. (NYSE:SUNE) quarterly performance is -65.11%.

SunEdison, Inc. (NYSE:SUNE) said that, it has won a bid to sell solar power in India at a record low tariff, which could boost the appeal of the renewable source at a time when Prime Minister Narendra Modi is pushing for clean energy to combat climate change.

Nokia Corporation (ADR) (NYSE:NOK) caters to the Technology space. It has a net profit margin of 30.40% and weekly performance is 15.20%. On the last day of trading company shares ended up at $7.58. Nokia Corporation (ADR) (NYSE:NOK) distance from 50-day simple moving average (SMA50) is 13.50%.

Nokia Corporation (ADR) (NYSE:NOK) said that the receipt of all the required regulatory approvals for its acquisition of French telecom equipment maker Alcatel-Lucent ( ), its board of directors has resolved to convene an extraordinary general meeting to be held on December 2, 2015.

Kite Pharma, Inc. (NASDAQ:KITE) shares increased 0.44% in last trading session and ended the day at $72.65. KITE has a return on assets of -15.20%. Kite Pharma, Inc. (NASDAQ:KITE) quarterly performance is -5.03%.

On 27 October, Kite Pharma, Inc. (NASDAQ:KITE) announced that it has entered into a worldwide research and license agreement with Alpine Immune Sciences, Inc. (AIS), a privately-held biotechnology company, to discover and develop protein-based immunotherapies targeting the immune synapse to treat cancer. AIS will grant Kite an exclusive license to two programs from its transmembrane immunomodulatory protein (TIP(TM)) technology, which Kite plans to further engineer into chimeric antigen receptor (CAR) and T cell receptor (TCR) product candidates.

Synchrony Financial (NYSE:SYF) caters to the Financial space. It has a net profit margin of 16.90% and weekly performance is 2.24%. On the last day of trading company shares ended up at $32.44. Synchrony Financial (NYSE:SYF) distance from 50-day simple moving average (SMA50) is 2.35%.

On 29 October, Synchrony Financial (NYSE:SYF) said that, it is proud to announce its participation in the Department of Defense Military Spouse Employment Partnership. Synchrony Financial officially joined the Military Spouse Employment Partnership on Wednesday at the annual Induction Ceremony held at the Mark Center in Alexandria, Virginia

Leave a Reply

Your email address will not be published. Required fields are marked *